



BERYL DRUGS LIMITED

Regd. Off.: Ground Floor, 133, Kanchan Bagh, Indore - 452001 (M.P.)

Tel. : (0731) 2517677 | E-mail : beryldrugs25@yahoo.com | CIN : L02423MP1993PLC007840

Date: 09.08.2022

To,

The Secretary,
Department of Corporate Services,
Bombay Stock Exchange Limited (BSE),
Phiroze Jeejeebhoy Towers, Dalal Street,
Mumbai – 400001

Scrip Code: 524606

Sub.: Disclosure of Regulation 30 read with Part- A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sirs,

Pursuant to Regulation 30 read with Part- A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board of Directors in its 40th Board Meeting held on 09.08.2022 has approved the Unaudited Financial Results of the Company for the Quarter ended 30.06.2022.

We hereby request you to kindly acknowledge the receipts of same.

Thanking You,

Yours Sincerely

For Beryl Drugs Limited



Sudhir Setti
Chairman & Director
DIN: 00090172



BERYL DRUGS LIMITED
Gr. Floor, 133, Kanchan Bagh, Indore (M.P.) – 452 001.
Tel./ Fax 0731-2517677
E-mail : beryldrugs25@yahoo.com

ANNEXURE I

Submission of Unaudited/ Audited Financial Result by Companies Other than Banks

Part I (Rs in Lakhs) except per share data

Statement of standalone Unaudited Result for the Quarter/year ended 30/06/2022

Particulars	Quarter ended		Year ended	
	3 months ended (30-06-2022)	Preceding 3 months ended (31-03-2022)	Corresponding 3 months ended in the previous year (30-06-2021)	Previous year ended (31-03-2022)
	Unaudited	Audited	Unaudited	Audited
(Refer Notes Below)				
1 Revenue From Operations				
Net sales or Revenue from Operations	493.24	346.91	460.98	1460.37
Other operating revenues	3.59	5.13	3.85	16.49
Total Revenue from operations (net)	496.83	352.04	464.83	1476.86
2 Expenses				
(a) Cost of materials consumed	283.15	278.82	246.01	870.72
(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-25.22	-39.70	-4.23	-30.41
(d) Employee benefit expense	33.32	28.83	30.49	131.09
(e) Finance costs	12.59	9.93	11.16	43.68
(f) Depreciation and amortisation expense	24.66	27.12	29.87	108.65
(g) Other Expenses	146.15	112.86	121.68	448.16
Total expenses	474.65	417.86	434.98	1571.89
3 Profit (loss) from operations before exceptional items and tax	22.18	-65.82	29.85	-95.03
4 Exceptional items	0.00	0.00	0.00	0.00
5 Profit (loss) before tax	22.18	-65.82	29.85	-95.03
6 Tax Expense				
Current tax	3.46	0.91	0.00	0.91
Mat Credit Entitlement	-3.46	0.00	0.00	0.00
Deferred tax	0.35	-19.29	-4.10	-30.04
Total Tax Expenses	0.35	-18.38	-4.10	-29.13
7 Net Profit (loss) for the period from continuing operations	21.83	-47.44	33.95	-65.90
8 Net Profit (loss) from discontinuing operations before tax	0.00	0.00	0.00	0.00
9 Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00
10 Net Profit (loss) from discontinuing operations after tax	0.00	0.00	0.00	0.00
11 Net Profit (loss) for the Period	21.83	-47.44	33.95	-65.90
12 Other comprehensive Income	-2.06	2.37	-3.72	2.32
13 Total Comprehensive Income	19.77	-45.07	30.23	-63.58
14 Details of equity share capital				
Paid-up equity share capital	507.17	507.17	507.17	507.17
Face value of equity share capital	10.00	10.00	10.00	10.00
15 Earnings per share (of Rs. 10 each)- for continuing operations				
i Basic	0.43	-0.94	0.67	-1.30
ii Diluted	0.43	-0.94	0.67	-1.30

1. The above financial results have been prepared in accordance with the recognition and measurement principles stated therein prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Agreement Regulation.

2. The above results for the quarter ended 30th June 2022 which have been subjected to Limited Review by Statutory Auditors of the Company were reviewed and recommended by the Audit Committee and subsequently by the Board of Directors at its meeting held on 09th August, 2022 in terms of regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation, 2015, as amended.

3. The Income from Operations is from one segment namely "Pharmaceutical Industry" as per Ind AS 108 "Operating Segments".

4. The figures for the quarter ended March 31, 2022 are balancing figures between audited figures in respect of full financial year ended March 31, 2022 and the unaudited published figure up to December 31, 2021 being the end of third quarter of the financial year which were subjected to limited review.

5. The figures for the previous periods have been regrouped/ reclassified wherever necessary to confirm to current period classification.

6. Depreciation is provided on Written down value method on the estimated remaining useful lives of the assets.

7. Revenue from Operations is net of GST.

8. Earnings per Share amount is Shown in Rupee.

BERYL DRUGS LIMITED
(Directo
For and behalf of the
Board
Sanjay Sethi
Managing Director

Place : Indore
Date : 09/08/2022

PRATEEK JAIN & CO.

CHARTERED ACCOUNTANTS

212, SHALIMAR CORPORATE CENTRE, 8-B, SOUTH TUKOGANJ,

INDORE (M.P.) 452001

PH. 9827013187, 731-2520955

E-MAIL: caprateekjain@gmail.com



Independent Auditor's Review Report on the Quarterly unaudited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To,
The Board of Directors
Beryl Drugs Limited
Indore (M.P.) - 452001

We have reviewed the accompanying statement of unaudited financial results of **BERYL DRUGS LIMITED** ("the Company") for the quarter ended **30th June, 2022** ("the statement") attached herewith, being submitted by the Company pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("the listing regulations").

This statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE 2410) "Review of Interim Financial Information Performed by Independent auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



PRATEEK JAIN & CO.

CHARTERED ACCOUNTANTS

212, SHALIMAR CORPORATE CENTRE, 8-B, SOUTH TUKOGANJ,

INDORE (M.P.) 452001

PH. 9827013187, 731-2520955

E-MAIL: caprateekjain@gmail.com



Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in all material respect in accordance with the applicable Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013 read with relevant rules there under and other recognized accounting practices generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR PRATEEK JAIN AND CO.
CHARTERED ACCOUNTANTS
FRN-009494C



Prateek Jain
PRATEEK JAIN
PROPRIETOR
M.NO.079214

Date: 9th August 2022

Place: Indore

UDIN: 22079214AOPUPE2528